ArticleNature neuroscience2024
TREM1 disrupts myeloid bioenergetics and cognitive function in aging and Alzheimer disease mouse models.
Open access · greenAbstract read
In one paragraph
Article in Nature neuroscience, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 35 papers, 2 of them syntheses that pooled it.
0numbers the graph read from it
0cells of the map it votes in
35citing papers in PubMed, 2 pooled it
10.3field-weighted citation impact, top 1% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
35 citing papers in PubMed, 2 syntheses or guidelines pooled it, 43 citations in OpenAlex.
- Proteome-wide Mendelian randomization identifies causal plasma proteins in frontotemporal dementia.Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology · 2026Pooled it
- Osteopontin in Alzheimer's Disease: A Double-Edged Sword in Neurodegeneration and Neuroprotection-A Systematic Review.CNS neuroscience & therapeutics · 2025Pooled it
- Research landscape of neurodegenerative diseases and brain energy metabolism: A multi-database integrative analysis.IBRO neuroscience reports · 2026Article
- Extracellular CIRP induces neurotoxic astrocytes via TREM-1 in Alzheimer's disease.bioRxiv : the preprint server for biology · 2026Article
- Article
- Soluble TREM1 Contributes to Aging-Related Neurodegeneration via ROBO2/ERK Pathway.Molecular neurobiology · 2026Article
- Brain-targeted delivery of siRNA via non-viral delivery systems, the therapeutic strategy for Alzheimer's disease-Unveiling challenges and prospects.International journal of pharmaceutics: X · 2026Review
- Triggering receptor expressed on myeloid cell family in atherosclerosis: from mechanisms to intervention strategies.Cell communication and signaling : CCS · 2026Review
- APOE-mediated lipid transport prevents C1q-related synaptic loss after spinal cord injury via attenuating macrophage lipid stress.Journal of neuroinflammation · 2026Article
- Immune dysfunction in Alzheimer disease.Nature reviews. Neuroscience · 2026Review
- Engineering Immune Cell to Counteract Aging and Aging-Associated Diseases.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026Review
- Functional border-associated macrophages limit Alzheimer's Disease progression.bioRxiv : the preprint server for biology · 2026Article
- Parkinson's disease: spatiotemporal regulation and therapeutic prospects of TREM2-mediated microglial responses.NPJ Parkinson's disease · 2026Review
- Article
- Neuroinflammation: a critical bridge linking peripheral pathology and age-related degeneration in myasthenia gravis.Frontiers in medicine · 2026Review
- The immune microenvironment and population heterogeneity in myasthenia gravis: implications for precision therapeutics.Frontiers in immunology · 2026Review
- Differential downstream signaling in microglia lacking Alzheimer's-related TREM2 or its adaptor TYROBP/DAP12.Molecular neurodegeneration advances · 2026Article
- The metabolic engine of cognition: microglia-neuron interactions in health, ageing and disease.Nature metabolism · 2025Review
- Triggering Receptor Expressed on Myeloid Cells-1 (TREM-1) in Inflammation and Disease: Mechanisms, Therapeutic Potential, and Future Directions.International journal of molecular sciences · 2025Review
- Plasma proteomic signatures of preclinical Alzheimer's disease biomarkers and memory in clinically unimpaired older adults.medRxiv : the preprint server for health sciences · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
32 authors at 5 institutions in 1 country.
Edward N WilsonDepartment of Neurology and Neurological Sciences, Stanford University School of Medicine, Stanford, CA, USA.ORCID http://orcid.org/0000-0003-0640-5247
Congcong WangDepartment of Neurology and Neurological Sciences, Stanford University School of Medicine, Stanford, CA, USA.
Michelle S SwarovskiDepartment of Neurology and Neurological Sciences, Stanford University School of Medicine, Stanford, CA, USA.
Kristy A ZeraDepartment of Neurology and Neurological Sciences, Stanford University School of Medicine, Stanford, CA, USA.
Hannah E EnnerfeltDepartment of Neurology and Neurological Sciences, Stanford University School of Medicine, Stanford, CA, USA.
Qian WangDepartment of Neurology and Neurological Sciences, Stanford University School of Medicine, Stanford, CA, USA.
Aisling ChaneyDepartment of Neurology and Neurological Sciences, Stanford University School of Medicine, Stanford, CA, USA.
Esha GaubaDepartment of Neurology and Neurological Sciences, Stanford University School of Medicine, Stanford, CA, USA.
Javier A Ramos BenitezDepartment of Neurology and Neurological Sciences, Stanford University School of Medicine, Stanford, CA, USA.
Yann Le GuenDepartment of Neurology and Neurological Sciences, Stanford University School of Medicine, Stanford, CA, USA.ORCID http://orcid.org/0000-0001-6649-8364
Paras S MinhasDepartment of Neurology and Neurological Sciences, Stanford University School of Medicine, Stanford, CA, USA.
Maharshi PanchalDepartment of Neurology and Neurological Sciences, Stanford University School of Medicine, Stanford, CA, USA.
Yuting J TanDepartment of Neurology and Neurological Sciences, Stanford University School of Medicine, Stanford, CA, USA.
Eran BlacherDepartment of Neurology and Neurological Sciences, Stanford University School of Medicine, Stanford, CA, USA.ORCID http://orcid.org/0000-0003-3207-0153
Chinyere A IwekaDepartment of Neurology and Neurological Sciences, Stanford University School of Medicine, Stanford, CA, USA.ORCID http://orcid.org/0000-0001-9228-2436
Haley CropperDepartment of Neurology and Neurological Sciences, Stanford University School of Medicine, Stanford, CA, USA.
Poorva JainDepartment of Neurology and Neurological Sciences, Stanford University School of Medicine, Stanford, CA, USA.
Qingkun LiuDepartment of Neurology and Neurological Sciences, Stanford University School of Medicine, Stanford, CA, USA.
Swapnil S MehtaDepartment of Neurology and Neurological Sciences, Stanford University School of Medicine, Stanford, CA, USA.
Abigail J ZuckermanDepartment of Neurology and Neurological Sciences, Stanford University School of Medicine, Stanford, CA, USA.
Matthew XinDepartment of Neurology and Neurological Sciences, Stanford University School of Medicine, Stanford, CA, USA.ORCID http://orcid.org/0000-0002-0896-2728
Jacob UmansDepartment of Neurology and Neurological Sciences, Stanford University School of Medicine, Stanford, CA, USA.
Jolie HuangDepartment of Neurology and Neurological Sciences, Stanford University School of Medicine, Stanford, CA, USA.
Aarooran S DurairajDepartment of Neurology and Neurological Sciences, Stanford University School of Medicine, Stanford, CA, USA.
Geidy E SerranoCivin Laboratory for Neuropathology, Banner Sun Health Research Institute, Sun City, AZ, USA.
Thomas G BeachCivin Laboratory for Neuropathology, Banner Sun Health Research Institute, Sun City, AZ, USA.
Michael D GreiciusDepartment of Neurology and Neurological Sciences, Stanford University School of Medicine, Stanford, CA, USA.
Michelle L JamesDepartment of Neurology and Neurological Sciences, Stanford University School of Medicine, Stanford, CA, USA.
Marion S BuckwalterDepartment of Neurology and Neurological Sciences, Stanford University School of Medicine, Stanford, CA, USA.
Melanie R McReynoldsLewis-Sigler Institute for Integrative Genomics, Princeton University, Princeton, NJ, USA.ORCID http://orcid.org/0000-0001-5427-2739
Joshua D RabinowitzLewis-Sigler Institute for Integrative Genomics, Princeton University, Princeton, NJ, USA.
Katrin I AndreassonDepartment of Neurology and Neurological Sciences, Stanford University School of Medicine, Stanford, CA, USA. kandreas@stanford.edu.ORCID http://orcid.org/0000-0001-8391-4155
Stanford University · USNeurosciences Institute · USBanner Sun Health Research Institute · USPennsylvania State University · USPrinceton University · US
Funding
Research Education ComponentP30AG019610 · NIA · SUN HEALTH RESEARCH INSTITUTE · PI REIMAN, ERIC MICHAEL · 2001 to 2020
$32.5MStanford Alzheimer's Disease Research CenterAdmin Supp: Developing iPSC models for AD and PDP30AG066515 · NIA · STANFORD UNIVERSITY · PI ELIZABETH MORMINO · 2020 to 2026
$29.0MResearch Education ComponentP30AG072980 · NIA · BANNER HEALTH · PI Nicholas Ashton · 2021 to 2026
$24.9MNational Brain and Tissue Resource for Parkinson's Disease and Related DisordersU24NS072026 · NINDS · BANNER SUN HEALTH RESEARCH INSTITUTE · PI BEACH, THOMAS G · 2011 to 2015
$7.8MThe role of TREM1 signaling in the development of Alzheimer’s diseaseRF1AG053001 · NIA · STANFORD UNIVERSITY · PI ANDREASSON, KATRIN I. · 2016 to 2016
$2.0MReprogramming myeloid cell metabolism to prevent cognitive aging and Alzheimer's DiseaseRF1AG070839 · NIA · STANFORD UNIVERSITY · PI ANDREASSON, KATRIN I. · 2021 to 2021
$1.9MModulating the post-stroke inflammatory response to improve outcome in models of cerebral ischemiaR01NS100180 · NINDS · STANFORD UNIVERSITY · PI ANDREASSON, KATRIN I. · 2018 to 2021
$1.8MThe role of peripheral versus brain myeloid immunity in the cognitive decline of aging and Alzheimer's diseaseRF1AG079131 · NIA · STANFORD UNIVERSITY · PI ANDREASSON, KATRIN I. · 2022 to 2022
$1.7MReprogramming myeloid cell metabolism to prevent cognitive aging and Alzheimer's DiseaseR01AG070839 · NIA · STANFORD UNIVERSITY · PI ANDREASSON, KATRIN I. · 2024 to 2025
$1.2MNIA NIH HHS P30 AG019610NIA NIH HHS P30 AG066515NIA NIH HHS P30 AG072980NIA NIH HHS R01 AG070839NIA NIH HHS RF1 AG053001NIA NIH HHS RF1 AG070839NIA NIH HHS RF1 AG079131NINDS NIH HHS R01 NS100180NINDS NIH HHS U24 NS072026
Abstract
Human genetics implicate defective myeloid responses in the development of late-onset Alzheimer disease. A decline in peripheral and brain myeloid metabolism, triggering maladaptive immune responses, is a feature of aging. The role of TREM1, a pro-inflammatory factor, in neurodegenerative diseases is unclear. Here we show that Trem1 deficiency prevents age-dependent changes in myeloid metabolism, inflammation and hippocampal memory function in mice. Trem1 deficiency rescues age-associated declines in ribose 5-phosphate. In vitro, Trem1-deficient microglia are resistant to amyloid-β
Indexed as
AgingAlzheimer DiseaseDisease Models, AnimalEnergy MetabolismMicrogliaTriggering Receptor Expressed on Myeloid Cells-1Amyloid beta-PeptidesAnimalsCognitionHippocampusMiceMice, Inbred C57BLMice, TransgenicAmyloid beta-PeptidesTREM1 protein, mouseTriggering Receptor Expressed on Myeloid Cells-1
Identifiers
What OpenQuestion holds
Textmetadata
LicenceTDM
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.